Table 7.

Minimal inhibitory concentration of telavancin and vancomycin against clinically relevant bacteria from a worldwide collection of clinical isolates

(data modified from Mendes et al. [57])

Organism (number tested)/antimicrobial agent	MIC50 (µg/mL)	MIC90 (µg/mL)	% Susceptiblea	% Intermediate	% Resistant
Staphylococcus aureus, MSSA (4230)
Telavancin	0.03	0.06	100	0	0
S. aureus, MRSA (2613)
Telavancin	0.03	0.06	100	0	0
Vancomycin	1	1	100	0	0
Enterococcus faecalis (702)
Telavancin	0.12	0.12	98.4
Vancomycin	1	2	98.4	0.2	1.4
E. faecium, vancomycin susceptible (228)
Telavancin	≤ 0.015	0.03
Vancomycin	1	1	100	0	0
S. pneumoniae (1878)
Telavancin	≤ 0.015	≤ 0.015
Vancomycin	0.25	0.5	100	0	0

CLSI Clinical and Laboratory Standards Institute, MIC minimal inhibitory concentration, MIC₅₀ MIC required to inhibit growth of 50% of organisms, MIC₉₀ MIC required to inhibit growth of 90% of organisms, MRSA methicillin-resistant S. aureus, MSSA methicillin-sensitive S. aureus

^aSusceptibility according to US Food and Drug Administration (FDA) interpretive breakpoints for telavancin and according to CLSI interpretive breakpoints for vancomycin